Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mediwound ( (MDWD) ) has shared an announcement.
On September 29, 2025, MediWound Ltd. announced a $30 million registered direct offering of ordinary shares, led by a U.S.-based mutual fund and other healthcare investors. The offering, expected to close on or about September 30, 2025, aims to support the pre-commercial activities of EscharEx, enhance manufacturing capabilities, and fund general corporate purposes, potentially strengthening MediWound’s market position and operational capacity.
The most recent analyst rating on (MDWD) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score reflects significant challenges in financial performance, particularly profitability and cash flow management. While there is potential for growth through clinical advancements and partnerships, current financial metrics and valuation concerns weigh heavily. Technical indicators suggest stability but lack strong momentum. The earnings call provides some optimism for future growth, but financial improvements are necessary for a more favorable outlook.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair. Its FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is available in the U.S., EU, Japan, and other markets. The company is also developing EscharEx®, an investigational therapy for chronic wound debridement, which targets a significant global market.
Average Trading Volume: 96,450
Technical Sentiment Signal: Sell
Current Market Cap: $193.4M
For a thorough assessment of MDWD stock, go to TipRanks’ Stock Analysis page.